Quantcast

Latest Gynecologic oncology Stories

2010-12-07 06:30:00

QUEBEC, Dec. 7 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS,TSX: AEZ) (the "Company") will hold an R&D Review for investors and analysts on Tuesday, December 14, 2010 from 4 p.m. to 6 p.m. (EST) in the Park Avenue Room of the InterContinental New York Barclay Hotel in New York City. Aeterna Zentaris' management will introduce the Company's robust pipeline, focused mainly on oncology, and will be available for further discussion. Detailed presentations of the Company's...

2010-12-01 06:30:00

CALGARY, Dec. 1 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today the start of enrollment in a randomized Phase II ovarian cancer study. The Gynecologic Oncology Group (GOG) is conducting the randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN((R)) in patients with persistent or recurrent ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study is being sponsored by the Cancer Therapy...

2010-11-10 00:00:42

Women's Oncology Research & Dialogue has lanched a new website to inform women about ovarian, uterine, cervical and all gynecologic cancers at wordoncancer.org. Indianapolis, IN (PRWEB) November 9, 2010 On November 9, 2010 Women's Oncology Research & Dialogue launched their new website at http://www.wordoncancer.org. WORD was founded with the mission of spreading awareness as well as offering insight and education on gynecologic cancers to the world. Founded by two gynecologic...

2010-10-25 07:00:00

AUSTIN, Texas, Oct. 25 /PRNewswire-FirstCall/ -- (Nasdaq: VRML) -- Fred Ueland, M.D., Associate Professor of Gynecologic Oncology at the University of Kentucky's Markey Cancer Center, and principal investigator of the multi-center OVA1(TM) clinical trial, today presented data demonstrating the high sensitivity of the OVA1 test at the 13th Annual International Gynecologic Cancer Society Meeting being held in Prague, October 23-26. Dr. Ueland's presentation demonstrated that OVA1 had...

2010-10-15 17:12:37

An internationally-recognized gynecologic oncologist at St. Joseph's Hospital and Medical Center in Phoenix, Arizona is warning that the results from a long-awaited global study of ovarian cancer should be viewed cautiously. Published in The Lancet last month, the study reported that women who received early chemotherapy for a recurrence of ovarian cancer did not live longer than those whose treatment is delayed. London-based, The Lancet  is one of the world's most respected medical...

2010-09-29 13:53:30

Intrauterine devices, originally developed as contraceptives, can also be used to treat and cure cancer of the endometrium according to new research published online in the cancer journal, Annals of Oncology [1] today (Wednesday 29 September). The finding opens the way for young women with the disease, which affects the lining of the womb, to be treated without the need for a hysterectomy, thus preserving their fertility until they have had all the children they want. Endometrial cancer is...

2010-09-08 16:22:00

VANCOUVER, Sept. 8 /PRNewswire/ - Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis. The research paper, ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas, published today in the New England Journal of Medicine. Researchers looked at over 600 samples of ovarian cancer, leading to the conclusion that the ARID1A mutation and loss of...

2010-09-08 16:04:00

VANCOUVER, Sept. 8 /PRNewswire/ - Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer. They are asking all BC gynecologists to change surgical practice to fully remove the fallopian tube when performing hysterectomy or tubal ligation. Current practice leaves the fallopian tube in place for many types of hysterectomy and tubal ligation. This is...

2010-09-08 07:00:00

PRESENTS "SCOPE OF EXCELLENCE" AWARDS Writer and Performer, Jenny Allen Will Emcee Brunch MORRISTOWN, N.J., Sept. 8 /PRNewswire-USNewswire/ -- The Kaleidoscope of Hope Foundation (KOH), a non-profit organization that raises awareness and funds and acts as the primary advocate for ovarian cancer activism in the New Jersey area, will be hosting their tenth anniversary celebration brunch, "A Zeal for Teal." The event will be held on Sunday, October 10, 2010 at the Hyatt Regency in New...

2010-09-02 06:30:00

TORONTO, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H). The study has been approved and will be sponsored by the Cancer Therapy Evaluation Program, Division of Cancer...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'